Kevin McKernan

And this whole personalized medicine thing was really looking like it was about to shine. So I was there for about five years.

And this whole personalized medicine thing was really looking like it was about to shine. So I was there for about five years.

Oh, they initially were going after – there was a group, Mike Stanton's group, I think, in Sanger Center used this to look at lung cancer. Glioblastoma got sequenced with it down in UCLA. And there was a group down at Baylor looking at breast cancer. I mean, it got used across the spectrum of different cancers, colon cancer.

Oh, they initially were going after – there was a group, Mike Stanton's group, I think, in Sanger Center used this to look at lung cancer. Glioblastoma got sequenced with it down in UCLA. And there was a group down at Baylor looking at breast cancer. I mean, it got used across the spectrum of different cancers, colon cancer.

Oh, they initially were going after – there was a group, Mike Stanton's group, I think, in Sanger Center used this to look at lung cancer. Glioblastoma got sequenced with it down in UCLA. And there was a group down at Baylor looking at breast cancer. I mean, it got used across the spectrum of different cancers, colon cancer.

I was on a paper with a group at Johns Hopkins. They're on top of the game with all the stuff down there at Bert Vogelstein's lab. And they were doing something very interesting with it in that.

I was on a paper with a group at Johns Hopkins. They're on top of the game with all the stuff down there at Bert Vogelstein's lab. And they were doing something very interesting with it in that.

I was on a paper with a group at Johns Hopkins. They're on top of the game with all the stuff down there at Bert Vogelstein's lab. And they were doing something very interesting with it in that.

Cancer, when you have it, oftentimes is sloughing dead cells out into your bloodstream. And if you sequence your bloodstream, you can kind of track which cells are dying from the cancer and look at their mutations and try to get a profile of whether the tumor is getting better or getting worse by just non-invasively sequencing bloodstreams.

Cancer, when you have it, oftentimes is sloughing dead cells out into your bloodstream. And if you sequence your bloodstream, you can kind of track which cells are dying from the cancer and look at their mutations and try to get a profile of whether the tumor is getting better or getting worse by just non-invasively sequencing bloodstreams.

Cancer, when you have it, oftentimes is sloughing dead cells out into your bloodstream. And if you sequence your bloodstream, you can kind of track which cells are dying from the cancer and look at their mutations and try to get a profile of whether the tumor is getting better or getting worse by just non-invasively sequencing bloodstreams.

So Rebecca Larry put out this paper where they did that, and we're scanning – people over time through the course of treatment by sequencing their bloodstream over time and developing markers that were very personalized to their tumor that would tell them that your particular tumor is going up or down based on what we're doing.

So Rebecca Larry put out this paper where they did that, and we're scanning – people over time through the course of treatment by sequencing their bloodstream over time and developing markers that were very personalized to their tumor that would tell them that your particular tumor is going up or down based on what we're doing.

So Rebecca Larry put out this paper where they did that, and we're scanning – people over time through the course of treatment by sequencing their bloodstream over time and developing markers that were very personalized to their tumor that would tell them that your particular tumor is going up or down based on what we're doing.

And the same tool got rolled into amino – sorry, I thought a little hot.

And the same tool got rolled into amino – sorry, I thought a little hot.

And the same tool got rolled into amino – sorry, I thought a little hot.

Amniocentesis. So the other thing circulating in mother's bloodstreams, around 6% of the DNA in a maternal bloodstream is actually the baby's. So if you don't want to do amnio, something that I'm sure you're familiar with given your recent father, amniocentesis has like a 1 in 400 fatality rate.

Amniocentesis. So the other thing circulating in mother's bloodstreams, around 6% of the DNA in a maternal bloodstream is actually the baby's. So if you don't want to do amnio, something that I'm sure you're familiar with given your recent father, amniocentesis has like a 1 in 400 fatality rate.

Amniocentesis. So the other thing circulating in mother's bloodstreams, around 6% of the DNA in a maternal bloodstream is actually the baby's. So if you don't want to do amnio, something that I'm sure you're familiar with given your recent father, amniocentesis has like a 1 in 400 fatality rate.